Actively Recruiting
LEVANTIS-0087A: GAGomes for Multi-Cancer Early Detection in Asymptomatic Adults (LEV87A)
Led by Elypta · Updated on 2024-09-19
9170
Participants Needed
1
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
LEVANTIS-0087A (LEV87A) is a retrospective in vitro diagnostics clinical validation population cohort-based case-control study to validate the diagnostic performance of free GAGome-based tests for multi-cancer early detection (MCED) in adults asymptomatic for cancer and with no recent history of cancer.
CONDITIONS
Official Title
LEVANTIS-0087A: GAGomes for Multi-Cancer Early Detection in Asymptomatic Adults (LEV87A)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 35 to 80 years at the baseline visit
- Any gender
- Not receiving treatment for or under surveillance for cancer at the baseline visit
- No signs of being monitored for or suspected of having cancer at the baseline visit
- No cancer diagnosis before or on the baseline visit, or any previous cancer was curatively treated at least 5 years before baseline
- Available biospecimens for both EDTA-plasma and urine at the baseline visit
You will not qualify if you...
- No available data for cancer diagnosis up to 365 days after the baseline visit
- Only a self-reported cancer diagnosis within 365 days after baseline without histopathological or clinical confirmation
- Subjects not matching the pre-specified target population criteria defined in the study analysis plan
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Elypta AB
Stockholm, Sweden
Actively Recruiting
Research Team
F
Francesco Gatto, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here